BiotechTube
Zenith Epigenetics

Zenith Epigenetics

Calgary, United States· Est.
zenithepigenetics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $42.5M

Overview

Zenith Epigenetics is a clinical-stage biotech based in Calgary, Canada, developing novel BET inhibitors (BETi) for oncology. The company's strategy centers on using its epigenetic platform to develop potent and selective BET inhibitors for use in combination with other targeted agents, aiming to enhance efficacy and combat resistance. Its lead asset, ZEN-3694, is advancing in a Phase 2 randomized trial for prostate cancer and several proof-of-concept studies in rare and aggressive cancers like NUT carcinoma, where it has received FDA Fast Track designation. Zenith operates through collaborations with leading oncology institutions and appears to be structured as a subsidiary or related entity of the public company Zenith Capital Corp.

Oncology

Technology Platform

Proprietary epigenetic platform for generating differentiated, potent, and selective bromodomain and extra-terminal (BET) protein inhibitors, integrated with translational medicine for biomarker and patient selection strategies.

Funding History

3
Total raised:$42.5M
Grant$2.5M
Series B$25M
Series A$15M

Opportunities

The FDA Fast Track designation for NUT carcinoma creates a potential accelerated path to market in a high-need, rare oncology indication.
Positive data from the broad proof-of-concept program could unlock significant value by demonstrating utility in large cancer markets like prostate, breast, and lung cancers, especially if biomarker strategies identify responsive patient populations.

Risk Factors

The BET inhibitor class has faced efficacy and toxicity challenges, creating clinical validation risk.
As a pre-revenue company with multiple concurrent trials, Zenith is heavily dependent on raising capital, exposing it to financial market volatility.
Intense competition from larger biopharma firms in the epigenetic space poses a threat to market share and partnership appeal.

Competitive Landscape

Zenith operates in the competitive BET inhibitor space, facing rivals like Bristol Myers Squibb (CC-90010), AbbVie, and Constellation Pharmaceuticals (acquired by MorphoSys). Its differentiation strategy relies on its compound's selectivity, combination-focused development, and translational medicine approach to identify responsive patients. Success hinges on demonstrating superior clinical profiles in targeted settings.

More companies in Small Molecule Drugs →More companies in United States →